139 related articles for article (PubMed ID: 11906965)
1. Anthrapyridones, a novel group of antitumour non-cross resistant anthraquinone analogues. Synthesis and molecular basis of the cytotoxic activity towards K562/DOX cells.
Tarasiuk J; Stefańska B; Plodzich I; Tkaczyk-Gobis K; Seksek O; Martelli S; Garnier-Suillerot A; Borowski E
Br J Pharmacol; 2002 Mar; 135(6):1513-23. PubMed ID: 11906965
[TBL] [Abstract][Full Text] [Related]
2. The role of structural factors in the kinetics of cellular uptake of pyrazoloacridines and pyrazolopyrimidoacridines: implications for overcoming multidrug resistance towards leukaemia K562/DOX cells.
Tarasiuk J; Majewska E; Seksek O; Rogacka D; Antonini I; Garnier-Suillerot A; Borowski E
Biochem Pharmacol; 2004 Nov; 68(9):1815-23. PubMed ID: 15450947
[TBL] [Abstract][Full Text] [Related]
3. Transport of new non-cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells.
Tkaczyk-Gobis K; Tarasiuk J; Seksek O; Stefanska B; Borowski E; Garnier-Suillerot A
Eur J Pharmacol; 2001 Feb; 413(2-3):131-41. PubMed ID: 11226386
[TBL] [Abstract][Full Text] [Related]
4. The effect of new non-cross resistant antitumour agents on the energy state of human erythrocytes.
Nowak R; Baranowska-Bosiacka I; Stefańska B; Machaliński B; Hłyńczak AJ; Tarasiuk J
Acta Biochim Pol; 2005; 52(4):953-7. PubMed ID: 16265591
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance.
Fang L; Zhang G; Li C; Zheng X; Zhu L; Xiao JJ; Szakacs G; Nadas J; Chan KK; Wang PG; Sun D
J Med Chem; 2006 Feb; 49(3):932-41. PubMed ID: 16451059
[TBL] [Abstract][Full Text] [Related]
6. The activity of latent benzoperimidine esters to inhibit P-glycoprotein and multidrug resistance-associated protein 1 dependent efflux of pirarubicin from several lines of multidrug resistant tumor cells.
Głowacka-Rogacka D; Arciemiuk M; Kupiec A; Bontemps-Gracz MM; Borowski E; Tarasiuk J
Cancer Detect Prev; 2004; 28(4):283-93. PubMed ID: 15350632
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents.
Dei S; Coronnello M; Bartolucci G; Manetti D; Romanelli MN; Udomtanakunchai C; Salerno M; Teodori E
Eur J Med Chem; 2018 Mar; 147():7-20. PubMed ID: 29421572
[TBL] [Abstract][Full Text] [Related]
8. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.
Mankhetkorn S; Dubru F; Hesschenbrouck J; Fiallo M; Garnier-Suillerot A
Mol Pharmacol; 1996 Mar; 49(3):532-9. PubMed ID: 8643093
[TBL] [Abstract][Full Text] [Related]
9. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
10. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol.
Arora A; Seth K; Kalra N; Shukla Y
Toxicol Appl Pharmacol; 2005 Feb; 202(3):237-43. PubMed ID: 15667829
[TBL] [Abstract][Full Text] [Related]
11. Reduction of doxorubicin resistance in P-glycoprotein overexpressing cells by hybrid cell-penetrating and drug-binding peptide.
Zheng Z; Aojula H; Clarke D
J Drug Target; 2010 Jul; 18(6):477-87. PubMed ID: 20088680
[TBL] [Abstract][Full Text] [Related]
12. Immunotoxin resistance in multidrug resistant cells.
McGrath MS; Rosenblum MG; Philips MR; Scheinberg DA
Cancer Res; 2003 Jan; 63(1):72-9. PubMed ID: 12517780
[TBL] [Abstract][Full Text] [Related]
13. Reversal effect of substituted 1,3-dimethyl-1H-quinoxalin-2-ones on multidrug resistance in adriamycin-resistant K562/A02 cells.
Sun LR; Li X; Cheng YN; Yuan HY; Chen MH; Tang W; Ward SG; Qu XJ
Biomed Pharmacother; 2009 Mar; 63(3):202-8. PubMed ID: 18818047
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells.
Munteanu E; Verdier M; Grandjean-Forestier F; Stenger C; Jayat-Vignoles C; Huet S; Robert J; Ratinaud MH
Biochem Pharmacol; 2006 Apr; 71(8):1162-74. PubMed ID: 16499877
[TBL] [Abstract][Full Text] [Related]
15. Relation between MDR1 mRNA levels, resistance factor, and the efficiency of P-glycoprotein-mediated efflux of pirarubicin in multidrug-resistant K562 sublines.
Meesungnoen J; Jay-Gerin JP; Mankhetkorn S
Can J Physiol Pharmacol; 2002 Nov; 80(11):1054-63. PubMed ID: 12489924
[TBL] [Abstract][Full Text] [Related]
16. Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells.
Xu D; Fang L; Zhu Q; Hu Y; He Q; Yang B
Pharmazie; 2008 Jul; 63(7):528-33. PubMed ID: 18717489
[TBL] [Abstract][Full Text] [Related]
17. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
18. Imatinib resistance in multidrug-resistant K562 human leukemic cells.
Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA
Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528
[TBL] [Abstract][Full Text] [Related]
19. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Xu HB; Li L; Liu GQ
Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of substituted dibenzo[c,e]azepine-5-ones as P-glycoprotein-mediated multidrug resistance reversal agents.
Tang X; Gu X; Ren Z; Ma Y; Lai Y; Peng H; Peng S; Zhang Y
Bioorg Med Chem Lett; 2012 Apr; 22(8):2675-80. PubMed ID: 22450134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
